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ABSTRACT
Obligate anaerobic bacteria are considered important constituents of the microbiota of humans; in
addition, they are also important etiological agents in some focal or invasive infections and
bacteremia with a high level of mortality. Conflicting data have accumulated over the last decades
regarding the extent in which these pathogens play an intrinsic role in bloodstream infections.
Clinical characteristics of anaerobic bloodstream infections do not differ from bacteremia caused by
other pathogens, but due to their longer generation time and rigorous growth requirements, it
usually takes longer to establish the etiological diagnosis. The introduction of matrix-assisted laser
desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) has represented a
technological revolution in microbiological diagnostics, which has allowed for the fast, accurate and
reliable identification of anaerobic bacteria at a low sample cost. The purpose of this review article is
to summarize the currently available literature data on the prevalence of anaerobic bacteremia in
adults for physicians and clinical microbiologists and to shed some light on the complexity of this
topic nowadays.
KEYWORDS
bacteremia, bloodstream infections, blood cultures, anaerobes, MALDI-TOF, Bacteroides, Clostridium
INTRODUCTION
Under physiological conditions, obligate anaerobic bacteria are considered important con-
stituents of the microbiota of humans; on mucosal surfaces and in some anatomical regions
(oral cavity, female genital tract, colon) their numbers exceed the number of facultative
anaerobes by a magnitude of 10–1,000 [1, 2]. These strict anaerobes have a protective role
against obligate pathogenic bacteria by consuming nutrients in the anatomical niche and by
secreting short-chain fatty acids (SCFAs); this phenomenon is called colonization resistance
[3]. Bacteria should be classified as strict anaerobes, if they are unable to replicate (i.e., to
form colonies) on solid media in the presence of atmospheric oxygen (18% O2 and 10% CO2)
[4]. The relevance of anaerobic bacteria as pathogens has been described from basically all
anatomical areas, these infections may be divided into two main groups: exogenous or
“classical” infections (botulism, gas gangrene, lockjaw) are predominantly monomicrobial,
toxin-mediated diseases, where the principal causative agents are spore-forming Gram-
positive rods (i.e., members of the Clostridium genus), while so-called endogenous or
“modern” infections are mainly polymicrobial (mixed aerobic-anaerobic) infections, where
the components of the normal bacterial microbiota are seen as pathogens [1, 2, 5, 6]. The
following anaerobes are accountable for the majority (>90%) of clinical infections: Gram-
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negative rods (Bacteroides/Parabacteroides spp., Prevotella
spp., Porphyromonas spp., Fusobacterium spp., Bilophila
spp., and Sutterella spp.), Gram-positive spore-forming
(Clostridium spp.) and non-spore-forming (Actinomyces
spp., Bifidobacterium spp., Eubacterium spp., and Cuti-
bacterium (Propionibacterium) spp.) rods and Gram-posi-
tive anaerobic cocci (GPAC) and Gram-negative cocci
(Veilonella spp. and Megasphera spp.) [7–11]. Based on the
source of the infection, Bacteroides/Parabacteroides spp. and
Clostridium spp. mainly originate from the gastrointestinal
tract, GPAC, pigmented Prevotella spp., Porphyromonas
spp., and Fusobacterium spp. arise from the upper airways,
from pulmonary sources or the female genital tract, while
Cutibacterium acnes mainly originated from the skin and
foreign bodies [1, 2, 12].
Several risk factors have been identified for the devel-
opment of anaerobic infections, such as cancer (solid tu-
mors or hematological malignancies), immunosuppression
associated with organ transplantation, corticosteroids,
cytotoxic agents or other types of immunosuppressing
factors (e.g., splenectomy, diabetes mellitus), gynecological,
gastrointestinal surgery or presence of decubitus ulcers [1,
2, 5, 6, 13]. From a clinical standpoint, anaerobic infections
should be suspected if the patients present with one or
more of the following: poor oral hygiene, foul-smelling
discharge, suppuration, abscess formation, thrombophle-
bitis, tissue destruction adjacent to relevant mucosal sur-
faces, infectious processes related to malignant diseases
(with no growth in aerobic cultivation methods), free gas in
the affected tissue (characteristic for gas gangrene), and
sulfur granules in histopathology (characteristic for acti-
nomycoses) among others [1, 2, 5, 6, 13, 14]. The clinical
relevance of anaerobic bacteria was further strengthened by
the emergence and spread of Clostridioides difficile (espe-
cially the hypervirulent, 027 ribotype), which is currently
considered as one of the most prevalent enteric nosocomial
pathogens in the 21st century and an important factor of
mortality [15, 16]. The therapy of anaerobic infections is
selected on empirical basis in most cases (with b-lactam
antibiotics, metronidazole or clindamycin being the most
frequently used agents), which is possible due to the more
or less predictable resistance patterns of these pathogens
[17–19]. However, some species possess genetically-deter-
mined resistance mechanisms (e.g., metronidazole-resis-
tance in the aerotolerant genera of Gram-positive rods,
macrolide and rifampin-resistance in Fusobacterium spp.,
cefoxitin-resistance in C. difficile), and the development of
resistance against b-lactam antibiotics (conferred by the
cfxA and cfiA genes) and metronidazole (conferred by the
nimA-K genes) is concerning [13, 19–22]. The number of
multidrug resistant (MDR) anaerobic strains, most
frequently members from the Bacteroides/Parabacteroides
spp. has also increased in the past decade; these de-
velopments highlight the importance of susceptibility
testing in anaerobes [23, 24].
In addition, qualitative and quantitative changes in the
human microbiome (including strict anaerobes) have been
associated with the development and exacerbation of various
chronic diseases, like depression, cardiovascular illnesses,
obesity, autoimmune disorders, rheumatoid arthritis, scle-
rosis multiplex and even autism [25–29]. For this reason,
there has been a shift in the interest towards anaerobic
bacteria and their virulence factors in the last several decades
[19, 30]. The primary requirement for the cultivation,
identification and susceptibility-testing of anaerobes is the
procurement of an adequate sample from the site of infec-
tion, preferably before the onset of antibiotic therapy, and
sending the sample to the laboratory for processing as soon
as possible [4, 31]. In addition, the availability of appropriate
laboratory infrastructure (pre-reduced anaerobically steril-
ized media for culturing anaerobes, devices capable of
generating and maintaining an anaerobic atmospheric such
as anaerobic jars and gas generator sachets, Anoxomat
systems, anaerobic chambers) is essential for the diagnostic
procedures of anaerobes [4, 19, 31]. Due to their fastidious
growth requirements, the economic considerations required
for anaerobic diagnosis and the lack of suitably qualified
specialists, species-level identification, antibiotic suscepti-
bility testing and typing of anaerobes were mainly per-
formed in reference laboratories [4]. Nevertheless, the
introduction of matrix-assisted laser desorption-ionization
time-of-flight mass spectrometry (MALDI-TOF MS) has
represented a technological revolution in clinical microbio-
logical diagnostics [32, 33]. This technology allows for
protein-based identification of microorganisms, based on
the separation and measurement of smaller to larger frag-
ments of highly conserved ribosomal proteins (which are
small and basic in character) by their mass to charge (m/z)
ratio [34]. In the MALDI-TOF MS measurements, the
protein spectrum of the clinical isolate is compared with the
protein spectrum of strains in the device-linked database
and expressed as a log score (microFlex; Bruker Daltonics)
or as a percentage (VITEK MS; bioMerieux), which provides
information on the level of match and security of identifi-
cation [35, 36]. Although the introduction of this method
was initially largely hindered by the high cost of the device, it
is now being used in more and more laboratories worldwide
[37]. The MALDI-TOF MS method (along with 16S RNA
gene sequencing) has now become the gold standard method
of anaerobic diagnostics, providing fast, accurate and reliable
results at a low sample cost, and the laboratory can therefore
provide information to the physicians within clinically
relevant time intervals (compared to presumptive
biochemical methods and kits) [38, 39]. Numerous inter-
national initiatives have focused on the development and
improvement of MALDI-TOF databases on anaerobic
pathogens (e.g., ENRIA: European Network for Rapid
Identification of Anaerobic Infections), allowing species-
level identification of pathogens that were previously not
possible [40, 41].
Anaerobic bacteria are important etiological agents in
some focal or invasive infections and bacteremia with a high
level of mortality; however, conflicting data has accumulated
over the last decades regarding the extent in which these
pathogens play an intrinsic role in bloodstream infections.
The purpose of this review article is to summarize the
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currently available literature data on the prevalence of
anaerobic bacteremia in adults for physicians and clinical
microbiologists and to shed some light on the complexity of
this topic nowadays.
ANAEROBIC BACTERIA IN BACTEREMIA
The processing of blood cultures is still considered to be one
of the most important tasks of clinical microbiological lab-
oratories [42]. Despite today’s modern healthcare, sepsis,
severe sepsis and septic shock still have a high mortality rate
(10–15, 20–25, and 40–60%, respectively), during which any
delay in the choice of adequate therapy reduces the patient’s
chances of survival [43–46]. Blood cultures nowadays are
mainly incubated in automated systems, which detect posi-
tive results (i.e., generation of bacteria in the sample) by
sensing changes in the level of CO2 within the bottles. The
time from insertion of the bottles to the positive signal is
termed time-to-positivity (TTP) of the blood culture, which
may be influenced by the generation time of the pathogens,
the initial inoculum in the flask, prior antibiotic exposure or
the chemical composition of the culture media used in the
bottles of the different blood culture systems [47]. The role
of consultative microbiology and the continuous profes-
sional collaboration between the microbiologist and clini-
cians is of paramount importance in the treatment of
bloodstream infections [48]. Anaerobes play an important
etiological role in many invasive infections and may be
clinically significant pathogens in bloodstream infections
and septicemia, despite their relatively low prevalence [49].
Transient bacteremia with an anaerobic component is
frequently associated with tooth extraction and dental sur-
geries (as the oral microbiome is rich in anaerobic bacteria),
but these bacteria are usually eliminated rapidly from the
bloodstream by a healthy immune system [50, 51]. It must
also be mentioned that the isolation of some anaerobic
species from the bloodstream (e.g., Clostridium septicum) is
significant as it may be the first indicator of colorectal cancer
[52].
Clinical characteristics of anaerobic bloodstream in-
fections do not differ from bacteremia caused by other (non-
anaerobic) pathogens, but due to the longer generation time
and rigorous growth requirements of these bacteria, it usu-
ally takes longer to establish the etiological diagnosis [49,
53]. Despite its infrequent occurrence, the mortality rate
associated with anaerobic bacteremia still remains very high
(ranging between 15 and 50%) [49, 53]. In general, Gram-
negative anaerobic rods (predominantly members of the
Bacteroides/Parabacteroides genus) are the most common in
bacteremia, followed by Clostridium species; however,
virtually the entire spectrum of anaerobic species has been
described (at least at a case level) as a pathogen causing
clinically significant bacteremia [48, 49, 53, 54]. Bacteroides/
Parabacteroides bacteremia is generally characterized by
thrombophlebitis, the presence of metastatic foci, hyper-
bilirubinemia, disseminated intravascular coagulation, while
Clostridium spp. bloodstream infections may include he-
moglobinuria, anemia, oliguria, and brownish discoloration
of the skin, in addition to the general systemic inflammatory
reaction [49, 53]. Numerous reports have reported the effect
of inappropriate empiric therapy on the mortality rate of
anaerobic sepsis, particularly when the therapy did not
include relevant anti-anaerobic agents, or the microor-
ganism was resistant to the empirical antibiotic therapy
received [55].
Anaerobic bacteremia mainly affects adults, with elderly
patients (>65 years) having high risk for developing
bacteremia with this etiology; in contrast, the prevalence of
anaerobes in bloodstream infections in neonates and chil-
dren is extremely rare (0–0.5% overall, with children be-
tween 2 and 6 years of age having the least risk) [49, 56]. In
general, early studies published between the 1960s and
1980s, the proportion of anaerobes in bacteremia was 20–
30%, while between 1980s and 1990s, this value was around
10–20% [49, 57]. However, after the 1990s, the ratio of
anaerobic bacteremia has decreased significantly, with
literature in the current decade suggesting their proportion
to be around 5% on average (ranging between 0.5 and 13%),
which corresponds to around 1 episode reported per 1,000
hospitalized patients [49, 58]. This decrease was suggested to
have occurred due to the introduction of the prophylactic
use of broad-spectrum antibiotic therapy (containing anti-
biotics with prophylactic anti-anaerobe activity), pre-oper-
ative treatments before bowel surgery, and the
“predictability” of anaerobic bacteremia, based on the risk
factors determined for these infections [48, 49]. Some au-
thors have gone as far as suggesting that anaerobic blood
cultures should only be used selectively, if the anamnestic
data or clinical signs and symptoms are suggestive of
anaerobic bacteremia [59]. In contrast, other studies have
suggested that the prevalence of anaerobic bacteremia is
actually increasing, corresponding with the higher number
of complex and invasive surgical procedures, immunosup-
pressed patients and patients requiring hospitalization in
tertiary-care hospitals [60]. Nevertheless, during the assess-
ment of these epidemiological studies, several variables
(geography, differences in the size and composition of study
populations, e.g., patient age, social status, underlying
immunocompromising conditions; antibiotic policies of the
healthcare-institution, treatment level of the hospital, e.g.,
primary vs. tertiary-care; identification methods used) need
to be considered, as these may significantly affect the re-
ported outcomes in these studies [48, 49, 57, 60].
EPIDEMIOLOGICAL STUDIES ON ANAEROBIC
BACTERIA IN ADULTS
In a very early review of 14 studies on anaerobic blood-
stream infections published by Finegold et al. corresponding
to the period between 1956 and 1974 has found, that the
female genital tract was the source of anaerobic bacteremia
in 20% of cases, while the gastrointestinal tract was the
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source in almost half of anaerobic bacteremias; sources were
unknown in only 6% of cases [61]. Lombardi et al. published
data regarding the epidemiology University of Michigan
Hospitals during 1987–1988; this publication has shown
similar findings to the study of Finegold et al.: 72% of pa-
tients with an anaerobic bloodstream infection had the
genito-urinary and gastrointestinal tracts as sources of
infection [62]. In addition to these reports, a survey con-
ducted by Morris et al. at Duke University Medical Center (a
1125-bed tertiary care hospital) from 1989 to 1991 indicated
that the source of infection was clinically obvious in 84% of
patients with anaerobic bacteremia [59]. They concluded
that because the types of infection causing anaerobic
bacteremia were generally predictable, anaerobic blood cul-
tures should only be performed selectively; at the same time
other researchers have echoed this recommendation, partly
because the rates of anaerobic bloodstream-infections in
their studies were rather low. Different members of Bacter-
oides/Parabacteroides spp., especially Bacteroides fragilis
were the most common blood isolates recovered from pa-
tients with anaerobic bacteremia; these organisms accounted
for approximately 55% of anaerobic bacteremias. B. fragilis
bacteremia was associated with intra-abdominal disease and
a very high mortality rate (19–40%), a 3.2-fold risk of
mortality and prolonged hospital stay. Associated risks for
mortality include alcoholism, chronic liver disease and
congestive heart failure [59]. Goldstein and Citron deter-
mined the relative annual isolation rate of anaerobic bacteria
and the susceptibility of B. fragilis group species isolated
during 1987 at two community hospitals in Los Angeles,
California. The relative frequencies of the isolation of n 5
261 strains were as follows: B. fragilis 61.0%; Bacteroides
thetaiotaomicron 17.0%; Parabacteroides distasonis 7.0%;
Bacteroides vulgatus 6.0%; Bacteroides ovatus 5.0%, and
Bacteroides uniformis 4.0%. They recovered n 5 8 (18.0%)
Clostridium spp., and n 5 2 (4.0%) Fusobacterium spp. [63].
One year later, Brook published clinical and microbiologic
data about 296 patients with anaerobic bacteremia surveyed
over 12 years in two military hospitals in the Greater
Washington DC area. Total of n5 212 Bacteroides spp. were
isolated, B. fragilis accounted for 78.0%, and B. thetaiotao-
micron for 14.0% of the cases; among other species, there
were 6.0% Fusobacterium isolates, 18.0% of various Clos-
tridium species and 15.0% of GPAC [64]. The primary
source bacteremia in these anaerobic bloodstream infections
were the gastrointestinal tract (42.0%), decubitus and
gangrene, the female genital tract and the oropharynx
(10.0%, respectively). Factors predisposing to anaerobic
bacteremia were abscesses and malignancy in case of n 5 53
patients each, surgery in n 5 30 patients and intestinal
obstruction and/or perforation in a minor group of patients
[64]. According to a review of Goldstein in 1996, the data
from earlier studies showed that anaerobes account for
∼20% of all bacteremia, but newer results showed that these
organisms account for approximately 4% (0.5%–9.0%) of
bacteremia at that time (or approximately one case per 1,000
admissions) [65]. Salonen et al. studied the incidence of
anaerobic bloodstream infections over 6 years (1991–1996)
retrospectively at the Turku University Central Hospital in
Finland. In this report, 4.0% of all bacteremia yielded
anaerobic bacteria and the isolation of these microorganisms
was clinically significant in 57 patients (0.18 cases per 1,000
admissions) [55]. According to their data, only 50.0% of these
patients received effective, appropriate antimicrobial therapy,
before the results of blood cultures were reported to the cli-
nicians; 18 patients (32.0%) got initially ineffective treatment,
which was later changed, because of the microbiological re-
sults and for 11 patients, treatment was not changed, even
after microbiological results became available. The mortality
in these patient groups were 18.0, 17.0, and 55.0%, respec-
tively [55]. In a study in the United Kingdom between 1969
and 1990, Grandsen et al. recovered n 5 250 anaerobic iso-
lates: 55.0% of these strains were among B. fragilis group
isolates, 12.0% Clostridium spp., 8.0% GPAC, and 7.0%
Fusobacterium spp [66]. Peraino et al. published data of a
350-bed community hospital in Santa Monica, California in
1991. They isolated n 5 48 different anaerobic strains from
20 patients and found that 6.2% of all positive blood cultures
anaerobes in them. 16 patients had clinically significant AB
and the outcome was fatal for 44.0% of these patients; two
patients died before results could be given to the clinicians
[67]. The source of infection was obvious for 68.0% of pa-
tients and half of patients were receiving appropriate anti-
microbial therapy, active against anaerobes. Their final
conclusion was that positive anaerobic blood cultures often
resulted in a change in the antimicrobial therapy, even though
anaerobic bacteremia was uncommon in their hospital [67].
Between 1987 and 1988, sixty-six patients at the University of
Michigan Hospitals (UMH) and nine patients at the Ann
Arbor Veteran’s Administration Medical Center (AVMC) in
the US were investigated by Lombardi et al. [68]. The ratio of
positive anaerobe blood cultures was 3.2% at the UMH and
1.8% at AVMC, the incidence of clinically significant AB at
the two hospitals were 0.68 and 0.54 per 1,000 patient ad-
missions, respectively. 38.0% of the patients had a fatal
outcome; among these, Bacteroides and Clostridium species
accounted for 90.0% of the isolates and in all of the fatal cases.
The source for anaerobic bacteremia was usually obvious;
gastrointestinal infections were the source in 66.0% of the
cases and was clearly implicated as the source of nearly all of
the fatal anaerobic bacteremias [68]. Ramos et al. reviewed a
total of n 5 231 patients observed over a period of six and a
half years in the Fundacion Jimenez Diaz Hospital, Madrid,
Spain and n 5 131 episodes of AB were retrospectively
analyzed with special attention given to microbiologic,
epidemiologic and clinical risk factors: the frequency of
anaerobic bacteremia was relatively high (7.5%) and clinical
significance was found in 66.0% of the episodes; attributable
mortality with anaerobic bacteremia was 32.0% [69]. The
isolation of Bacteroides/Parabacteroides spp. was clinically
significant in 89.0%, while in case of Clostridium spp., this was
only 33.0% of cases. The presence of a serious underlying
disease or septic shock, renal failure, inappropriate antimi-
crobial treatment and the absence of drainage or surgical
intervention for the septic foci were considered risk factors
associated with a bad prognosis [69].
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The incidence of anaerobic bacteremia was studied
retrospectively, over 62 months (between January 1999 and
March 2004) at Mont-Godinne University Hospital, Yvoir (a
380-bed tertiary-care teaching hospital) in Belgium by
Blairon et al. [70]. During this study, the distribution of
organisms, clinical presentations, choice of antimicrobial
therapy and clinical outcome were analyzed. The proportion
of positive blood cultures yielding obligate anaerobes was
3.3%, the overall incidence of clinically significant anaerobic
bacteremia was 0.51 cases/1,000 patient admissions (0.61
cases/10,000 hospital-days); these figures were significantly
higher in patients with active hematological malignancies
(5.97/10,000 vs. 0.33/10,000 hospital-days). Bacteroides/
Parabacteroides spp. accounted for 61.0% of isolates, fol-
lowed by Clostridium spp. (12.2%), GPAC and surprisingly
the Leptotrichia spp. (7.3% each) and Fusobacterium spp.
(4.8%). In this study, the most common risk-factors were
gastrointestinal surgery (half of the patients) and hemato-
logical malignancies with chemotherapy and/or bone
marrow graft (47.0%), one or more co-morbidities were
present in 77.5% of the 39 patients. The lower gastrointes-
tinal tract and the oropharynx were the two most frequent
proven sources of bacteremia; the overall mortality rate was
13%. According to their experiences, the fatal outcome
correlated with the severity of existent underlying diseases
and the immunosuppressed status of the patients, rather
than with the causative pathogen or the effectiveness of
antimicrobial therapy [70]. Another report from Belgium
published by De Keukeleire et al. identified the current sit-
uation of anaerobic bacteremia in the University Hospital
Brussel in a 10-year retrospective study, which presented
data between 2004 and 2013. The cases of anaerobic
bacteremia per 100,000 patient days decreased from 17.3 in
the period from 2004 to 2008 to 13.7 in the period 2009 to
2013, furthermore, the mean incidence of anaerobic blood-
stream infections decreased during the study period (1.27/
1,000 patients in 2004 vs. 0.94/1,000 patients in 2013) [71].
In case of these two study periods, a total of 437 different
anaerobic bacterial strains was isolated, with an average of
33 cases of anaerobic bacteremia per year during 2004–2008,
compared to an average of 27 cases per year during 2009–
2013 (corresponding to a decrease by 19% between the first
and the second study-period). In contrast, the proportion of
isolated anaerobic bacteremia, compared to the number of
all bacteremia remained stable at 5%. Similarly to previous
reports described above, Bacteroides/Parabacteroides spp.
accounted for 47.1% of the isolates, followed by 14.4%
Clostridium spp., 12.6% non-spore-forming Gram-positive
rods, 10.5% GPAC, 8.2% Prevotella spp. and other Gram-
negative rods and 7.1% Fusobacterium spp. The lower
gastrointestinal tract (around 50%) and wound-, skin- and
soft-tissue infections were the two most frequent sources for
anaerobic bacteremia, while the origin was unknown in 21%
of cases; the overall mortality rate was 14% [71]. Kim et al.
investigated the incidence and risk factors related to mor-
tality and assessed clinical outcomes of anaerobic bacteremia
in 2012 on the patients who were hospitalized at Severance
Hospital (a 2,000-bed university tertiary referral hospital) in
Seoul, Korea. They followed the tendencies in AB retro-
spectively in this institution since 1974 and found that the
incidence of anaerobic blood infections has gradually
increased in the last four decades, from 1.39% in 1974–1983
to 1.96% in 2007–2008. As they remarked, there were some
important technological changes in blood culture equipment
in their institution, blood culture systems from conventional
anaerobic broth blood systems to BACTEC 9240 systems
(Becton Dickinson Diagnostic Instrument Systems) in 1997,
while to BacT/Alert 3D systems (bioMerieux) in 2005,
however, the steady increase was observed during these
decades [72]. According to their nationwide annual report,
the number of elderly patients and patients with serious
underlying diseases such as malignancies has steadily
increased and indeed, patients admitted to their tertiary care
referral center hospital often present with more comorbid-
ities and several advanced diseases. A novel finding in their
study was that cardiovascular disease emerged as an
important underlying condition, which was significantly
associated with higher mortality: the authors assumed that
this change in patient population attributed to the increasing
trend what was noted [72]. In a publication by Cockerill
et al., corresponding to the period between 1984 and 1992, a
steady increase in the incidence of anaerobic bacteremia was
noted at the Mayo Clinic, and later, another retrospective
study report from the same institution also observed an
increase in incidence during the subsequent 12-year period
(from 1993 through 2004) [73]. In a 12-year study at an
Australian general hospital, Riley and Arvavena found a
200% increase in the incidence of anaerobic bacteremia, with
Fusobacterium species and GPAC being more frequently
identified [74].
In contrast, other reports provided no evidence of an
increase in the incidence of anaerobic sepsis or bacteremia:
Chandler et al. reviewed the relevance of blood cultures in a
5-year (1994–1999) retrospective study, in context of an
older population: they found that the prevalence of anaer-
obic bacteria may be as low as 0.14%, and in 92% of cases,
the anaerobic infection could be suspected based on clinical
presentation of the patients [75]. Similar results were shown
by Ortiz et al. in a 3-year study (1994–1996), where the
prevalence of anaerobic bacteremia was lower than 0.5% and
all these cases had an obvious source of infection [76]. To
highlight the minor role of anaerobic bacteremia in children,
Gene et al. showed that anaerobes only represented 0.02% of
isolates from anaerobically incubated blood cultures over a
2-year period [77]. Fenner et al. retrospectively analyzed
blood culture data for a 10-year period between 1997 and
2006 from University Hospital Basel, Switzerland (a 680-bed
tertiary care center in Switzerland, with 27,000 inpatients
and 167,000 outpatients per year). A total of 114,338 blood
cultures were submitted to the laboratory, from which, 1,084
(0.95%) anaerobic organisms were isolated; they have found
that the number of positive anaerobic blood cultures
decreased in the period from 1997 to 2001 (12.6 per 1,000
blood cultures performed) to 7.0, compared to the period
from 2002 to 2006. Similar observations were found, if the
proportion of isolated anaerobic organisms were compared
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to the number of all organisms isolated from blood cultures
(7.6%–4.3%). The number of patients with anaerobic
bacteremia significantly decreased from n 5 122 in 1997 to
n 5 69 in 2006, but on the other hand, the proportion of
Bacteroides/Parabacteroides spp. and GPAC increased
(26.8%–36.7% and 5.4%–12% respectively) [78]. Authors
from the St. Barnabas Hospital, a 450-bed community
hospital in the Bronx, New York, which served a predomi-
nantly black and Hispanic community, reviewed their data
with anaerobic bacteremia during 2000–2006. This health
institution provided care for patients in various medical
fields (internal medicine, surgery, oncology, substance abuse,
psychiatric, obstetrics and gynecology, neonatal medicine),
but the oncology service accounts only for <1% of admis-
sions [79]. The authors did not find an increase in the
incidence of anaerobic bacteremia in the study period:
anaerobic organisms accounted for less, than 2% of positive
blood culture results (range: 0.7–1.3%) and the number of
positive anaerobic culture results per 1,000 blood cultures
performed was 0.73, which is less than the rate of 1.68
positive results per 1,000 blood cultures that was reported by
Lassmann et al. for the period between 1993 and 1996 [60].
B. fragilis accounted for 33.0% of anaerobes, followed by
GPAC (19.0%). The etiology of infections was unknown in
42.0% of the cases, 32.0% of cases had an abdominal or
urogenital source, whereas 23.5% of cases involved skin and
soft-tissue infections. The anaerobic blood culture bottle is
routinely used in Japan with little discussion as to its justi-
fication or validity. Saito et al. retrospectively studied the
incidence of anaerobic bloodstream infections and the po-
tential risk factors of AB during a 2-year period (1999–2000)
at four university hospitals and one community hospital in
Japan. Thirty-four of 18,310 aerobic and anaerobic blood
culture sets from 6,215 patients taken at the university
hospitals, and 35 of 2,464 samples taken from 838 patients at
the community hospital, yielded obligate anaerobes. Bac-
teroides species and Clostridium species accounted for 60%
of the isolates. Fifty-seven patients from 69 blood culture
sets containing anaerobes had clinically significant anaerobic
bacteremia, among these 57 patients, almost half were
oncology patients, 40 (70%) had an obvious source of
anaerobic infection, 15 (26%) had recent surgery and/or
were in an immunosuppressed state. Their recovery rate of
isolated obligate anaerobes was low and the patients with
anaerobic bacteremia had limited number of underlying
diseases or potential risk factors for anaerobic infections
[80]. Another Japanese study made by Iwata et al. performed
a retrospective chart review at a private hospital for patients
admitted between July 1, 2004 and June 30, 2005 to deter-
mine patient characteristics resulting in anaerobic blood
culture. During the study period, 17,775 blood culture bot-
tles were sent for analysis, and 2,132 bottles (12.0%) were
positive for microbial growth. Only 47 cases were detected
by anaerobic cultures alone, among those, obligate anaerobes
represented 12 cases [81]. Clinical evaluation could have
predicted 7 of 12 cases of anaerobic bacteremia, in the
remaining 5 cases, the source of bacteremia was unclear.
There were 2.7 cases of anaerobic bacteremia per 1,000
blood cultures. The mortality attributable to anaerobic
bacteremia was very high (50%). As a conclusion, all the
abovementioned studies have suggested that the selective use
of anaerobic blood cultures needs to be considered, instead
of the traditionally used setup of taking blood culture sam-
ples for both aerobic and anaerobic workup. According to
their suggestions, the patients could be identified clinically;
and if it is likely that they will have anaerobic bacteremia
with a high degree of predictability, they should be treated
empirically without the need for microbiological confirma-
tion [75–81].
Nevertheless, several reports highlight that anaerobic
bacteremia may often be missed on the basis of clinical
findings, which result in patients receiving inadequate
antimicrobial treatment [48, 49, 82]. This is especially true
for patients undergoing invasive surgical interventions
(resulting in the disruption of physical barriers) and inten-
sive cytotoxic chemotherapy regimens (causing profound
neutropenia); in these cases, the normal microflora of the
patients may enter into the bloodstream, causing bacteremia
[48, 49, 82]. In the clinical study of Zahar et al. only one-
third of patients received appropriate antibiotic therapy
before the availability of microbiology results, and around
the same amount of patients never received appropriate
therapy. B. fragilis was represented as the most common
isolate, and the overall mortality rate in this study was high
(42%) [83]. Minces et al. collected cases of bacteremia and
endocarditis caused by Peptostreptococcus spp. and found
that most of affected patients suffered from some type of
malignancy [84]. Umemura et al. compared the clinical
characteristics of patients with anaerobic bacteremia with
those with aerobic bacteremia between January 1999 to
December 2012 in Aichi Medical University Hospital, Japan.
Clinical information for 71 patients corresponding to
anaerobic bacteremia was collected and they found an as-
sociation between anaerobic bacteremia and malignancy,
Douglas’ pouch drains and chest drains as the primary
causative of bacteremia, as well as associations between
anaerobic bacteremia and the gastrointestinal tract; however,
having a central venous catheter was not associated with
anaerobic bacteremia [85]. In the same institution between
January 2005 and December 2014 they treated 74 patients
with anaerobic bacteremia. This later retrospective case-
controlled study they performed to assess the prognostic
factors associated with death from anaerobic bacteremia, the
clinical and microbiological information included antibiotic
susceptibility was used for analysis of prognostic factors for a
30-day mortality. They found the association between the
30-day mortality rate and malignancy and clindamycin
resistance [86]. Anaerobic bacteremia was studied in n 5 32
patients in a four-year retrospective analysis by Kornowski
et al. between 1984 and 1988 among internal medicine pa-
tients in a 700-bed University Hospital, Tel Aviv, Israel.
Overall, anaerobic bacteria accounted for 4.5% of positive
blood cultures from the medicine service during this
period, the main causative organisms were among the
Clostridium and Bacteroides/Parabacteroides spp. AB
occurred either following invasive (non-surgical) procedures
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or spontaneously; the gastrointestinal tract was affected most
often, followed by the respiratory and urinary tracts and
malignancy was the most common underlying disease. The
fatality rate was 25.0% (but their patients’ mean age was 72
years) [87]. An additional study from Israel by Lazarovitch
et al. from the Harofeh University Medical Center, Zeriffin,
investigated the prevalence of anaerobic bacteremias and
evaluated the importance of anaerobic blood cultures from
January 1998 to December 2007. AB and sepsis decreased
during that period, but significant increase was observed the
proportion of Bacteroides/Parabacteroides species isolated
from blood cultures (from 18.0% during 1998–2002 to
43.0% during 2003–2007). Comparison of the medical data
of n 5 54 patients with Bacteroides-related bacteremia
during the two study periods (1998–1999 and 2006–2007)
revealed a marked increase in serious and heterogenous
underlying diseases. Hypertension and Type II diabetes were
found in 29.0% of the patients in 1998–1999 and increased
to 43–45% of the patients in 2006–2007, while ischemic
heart disease also increased from 14.0% in 1998–1999 to
43.0% in 2006–2007. Their conclusion was that, despite the
fact that positive anaerobic blood cultures account for a
small amount of all positive blood cultures, the growing
involvement of Bacteroides/Parabacteroides species-related
bacteremias together with an increased ratio of complex
underlying diseases in these patients emphasize the impor-
tance of anaerobic blood cultures [88]. Arzese et al. found n
5 225 anaerobic isolates in a nationwide survey of anaerobic
bacteremia in Italy, between 1991 and 1992: 34.0% of
anaerobic isolates were members of the Bacteroides/Para-
bacteroides spp., 11.0% Clostridium spp., 8.0% GPAC and
6.0% Fusobacterium spp. In the other subsequent Italian
study from a Northern-Bari Hospital, which was conducted
between 2008 and the first quarter of 2013, twenty-six pa-
tients were found positive for anaerobic bacteria with an
average of 1.28% of positive anaerobic blood cultures [89].
Their analysis shows that the percentage of blood cultures
positive for anaerobes was constant temporally, except for a
small drop in 2012, despite the greater number of blood
cultures being tested. Most cases of sepsis were caused by
anaerobic bacteria belonging to the Bacteroides/Para-
bacteroides spp.; however, they found a high incidence of
events caused by C. acnes [89]. Grohs et al. also aimed to
ascertain the relevance of routine anaerobic blood cultures in
France: during 2004, peripheral blood samples were incu-
bated in a BacT/Alert system. In their report, 13.7% of pa-
tients had a positive blood culture overall, including 1.2%
strict anaerobic bacteria. In addition to pointing out that
anaerobes are important etiological agents, the relevance of
anaerobic blood cultures were further shown in their insti-
tution, as facultative anaerobes had shorted TTP values in
these bottles [90]. Vena et al. aimed to perform a retro-
spective analysis of 10-years’ experience in a tertiary Uni-
versity hospital in Madrid, Spain to investigate the incidence,
prognosis and need to perform blood cultures for anaerobic
bacteria from 2003 to 2012. Overall incidence of anaerobic
bacteremia was 1.2 episodes/1,000 admissions, with no sig-
nificant changes during the 10-year study period; similarly
to findings of other studies, B. fragilis group (38.1%) and
Clostridium spp. (13.7%) were the most frequent isolated
microorganisms. 43.4% of the patients had a comorbidity
classified as ultimately fatal or rapidly fatal, clinical mani-
festations suggestive of anaerobic involvement were present
in only 55.0% of the patients, however, 24.8% of their pa-
tients died during the hospitalization. Independent predic-
tive factors of mortality were presentation with septic shock,
whereas, an adequate source control of the infection was
associated with a better outcome [56]. Anuradha et al.
reviewed cases of anaerobic bacteremia over a two-year
period in Mumbai, India. Out of n 5 93 blood cultures
received with a suspicion of anaerobic bacteremia, only
18.3% showed anaerobic growth. n 5 20 anaerobes were
detected as single isolates, while five had a polymicrobial
flora; the anaerobes isolated were GPAC, B. fragilis group,
Bilophila, and Eubacterium species. Seven of these patients
(4.3%) had a pre-existing heart condition, while others had a
prior history of surgery, diabetes mellitus or urinary tract
infection; the oropharynx was the most frequent portal of
entry, followed by the gastrointestinal tract. In this study,
fifteen patients developed major complications, such as
congestive cardiac failure, systemic embolization and per-
forative peritonitis, the mortality rate among the cases of
anaerobic bacteremia was 23.5% [91]. Muttaiyah et al.
investigated a 2-year study period at the Auckland City
Hospital, Auckland, New Zealand: anaerobes were isolated
from n 5 140 blood culture sets, taken from 114 patients, in
n 5 59, these isolates were considered as contaminants; of
their note, all Cutibacterium spp. were considered as con-
taminants. In patients with true anaerobic bacteremia, the
most likely source of infection was intra-abdominal (50.0%),
mucositis associated with neutropenia, contributed to by
cytotoxic therapy (19.0%), and a smaller number of cases
associated with skin and soft tissue-, pelvic- and oropha-
ryngeal infections. Thirty-five patients were on appropriate
therapy, prior to the availability of culture results, n 5 5
patients died, but only one death was directly attributable to
AB; antimicrobial therapy provided appropriate cover for
two-thirds of the patients [92]. In Hungary, two studies are
available from the same institution in two distinct time pe-
riods; in the report by Urban et al., n 5 305 anaerobic
species were isolated, corresponding to the period between
2005 and 2009, which a pronounced decreasing tendency in
the ratio of anaerobic isolates during the 5-year period (from
6.3% to 4.0%). Among the clinically-relevant isolates, Clos-
tridium spp. and Bacteroides/Parabacteroides spp. were the
most common, however, the majority (57.7%) of isolates
were Cutibacterium spp., reported as contaminants. The
average age of affected patients were 60 years and the crude
30-day mortality rate was shown to be 22.3% [48]. Gajdacs
et al. performed a similar epidemiological study, corre-
sponding to the time period between 2013 and 2017; in this
5-year period, n 5 423 strict anaerobes isolated, corre-
sponding to 3.3–3.6% of positive blood culture isolates or 1
per 1,000 hospitalized patients [93]. In the second study
period, the average age of the patients increased significantly
(72 years), while the species-distribution did not change
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drastically, compared to the study of Urban et al. [48, 93].
However, it must be noted that novel anaerobic species, not
detected in blood cultures previously in this geographical
region, were reported in this study, owing to the introduc-
tion of a MALDI-based diagnostic platform [93]. Some
studies aimed to assess the epidemiology of specific anaer-
obic pathogens: in a study from Sweden, Badri et al. retro-
spectively assessed the clinical and microbiological features
of anaerobic bacteremia in adults, caused by GPACs be-
tween 2012 and 2016; n5 226 episodes of GPAC bacteremia
(3.4 cases were recorded by using MALDI-TOF MS and 16S
rRNA gene sequencing as diagnostic modalities. In this
study, the 30-day crude mortality was 11%, while the most
common species were Anaerococcus spp. (>50%) [94]. In a
hospital-based case series, Almohaya et al. highlighted the
increase in the numbers of Lemierre syndrome and bacter-
emia caused by Fusobacterium spp. in Saudi Arabia; during
their analysis, the authors found 205 individual cases re-
ported from their country, in addition on the two cases they
have presented between 2015 and 2019 [95]. A study by
Stabler et al. from France evaluated the relevance of Clos-
tridium spp. bacteremia between 2010 and 2018, including n
5 81 patients, with at least one positive anaerobic blood
culture for Clostridium spp.; the 30-day crude mortality
observed in patients was 31.4%, and the administration of
the adequate antibiotic therapy was associated with
increased survival (P 5 0.03) [96]. Finally, a recently pub-
lished article from France by Lafaurie et al. noted n 5 209
positive anaerobic bottles in a 6-month survey period: most
of the isolates (60.3%) were contaminants, while true
anaerobic bacteremia was detected in 13 patients (out of
which 9 had underlying gastro-intestinal illness) [97].
ROLE OF ADVANCES IN DIAGNOSTIC
PROCEDURES
Previously, the identification of strict anaerobes in clinical
samples mainly relied on in-house, classical biochemical
testing, biochemical test strips (e.g., API ID32A Kit, RapidID
ANA II System) or automated systems (VITEK ANC Card)
and gas-liquid chromatography (GLC) [19, 98, 99]. These
methods were quite pricy, were available in only a few
diagnostic laboratories and provided identification results
only 48–72 hours later, mostly on the genus level [19, 98,
99]. Recent publications have pointed out that the intro-
duction of novel technological modalities (e.g., PCR,
MALDI-TOF MS, 16S rRNA sequencing, automation) into
the routine diagnostic workflow affected both the qualitative
and quantitative aspects of anaerobic bacteremia [19, 100–
102]. As these technologies have become available to a
growing number of laboratories, rapid, accurate and reliable
identification of anaerobes on species-level in a clinically-
relevant time-frame has become more common [32–36].
MALDI-based analysis may also have application in detec-
tion of resistance in anaerobes (e.g., differentiation of cfiA-
negative and cfiA-positive B. fragilis strains [103]) or in
typing (e.g., discrimination of different phylotypes of
C. acnes [104]). Shannon et al. have also reported on the
methodology called “early MALDI”, where short-term (4–6
hours) incubation of subcultures of positive anaerobic blood
culture bottles was shown to be a reliable method for at least
genus-level identification of common anaerobic species. The
study group has concluded that the utilization and perfec-
tion of the “early MALDI” highlights the role of mass
spectrometric analysis as a superior and more cost-effective
method for identification than sequencing [105]. In addi-
tion, there have been continuous developments in improving
and complementing databases of bacterial spectra for
MALDI-TOF analysis, to also be appropriate for the detec-
tion and differentiation of rarely occurring or taxonomically
close microorganisms [106]. In parallel, the characterization
of yet unknown bacterial species in the microbiome of
humans has occurred with the use of metagenomic tech-
nologies and next-generation sequencing; since the 2010s, as
many as 200–300 novel bacterial species (spec. nov.) are
being annotated each year [107, 108]. As a result of these
developments, several “new”, so far unknown anaerobic
species have been described as causative agents in bacter-
emia and invasive infections, which were not previously
reported as possible pathogens, resulting in an explosion of
publications and case reports. As an example, in our most
recent study between 2013 and 2017, five different species of
Gram-positive anaerobes (namely Actinotignum schaali,
Collinsella aerofaciens, Flavonifractor plautii, Solobacterium
moorei and Tissierella praeacuta) were described as causative
agents in bacteremia, which had not been previously re-
ported in Hungary before; in addition, compared to the
previous study performed between 2005 and 2009, a
significantly higher number of species was detected in the
more recent report (26 vs. 38 different species) [48, 93].
Nonetheless, the publishing of the “first reports” of clinical
relevance in bacteremia for A. schaali [109], Anaerobio-
spirillum succiniproducens [110], Butyricimonas virosa [111],
Capnocytophaga gingivalis [112], Desulfovibrio desulfuricans
[113], Dysgonomonas mossii [114], Fenollaria massiliensis
[115], Propionimicrobium lymphophilum [116], S. moorei
[117], Slackia exigua [118] and T. praeacuta [119] among
others, were possible due to mass spectrometry-based
bacteriological diagnostics. It should be expected that further
novel “emerging” strict anaerobic species will be described as
pathogens in bacteremia in the coming years.
CONCLUSIONS
Anaerobes are important components of the conventional
human microbiota and they are also common etiological
agents in the infections of virtually all anatomical sites,
including bacteremia. The early recognition and adequate
therapy of these infections is of great importance, as the
mortality rate associated with these infections is still pro-
nounced. The aim of this present review was to summarize
the literature available on the epidemiology of anaerobic
8 European Journal of Microbiology and Immunology
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
EUJMI-2020.00009_proof  11 May 2020  5:36 pm
bacteremia in adults. As presented above, conflicting data
have accumulated in the literature regarding the incidence of
anaerobic bacteremia and on the relevance of the routine use
of anaerobic blood cultures. The latter may be helpful when
obligate anaerobes give rise to bacteremia which may be
clinically suspected in patients with advanced age and/or in
severely immunocompromised states, having undergone
complex surgeries or having serious underlying diseases. The
introduction of MALDI-TOF MS and sequencing has
changed the face of diagnostic microbiology, which has a
definite effect on anaerobic bacteriology. In addition, culti-
vation of these bacteria is also important for susceptibility-
testing purposes, as many anaerobic species besides the Bac-
teroides/Parabacteroides spp. have developed beta-lactamase
activity; with multiple changes in the resistance patterns of
anaerobes, one can expect that therapeutic problems in the
future will be compounded by abandonment of the “complete
bacteriology” of blood cultures. The prevalence of anaerobic
bacteremia in relation to patient demographics should be
determined on an institution by an institutional basis to guide
blood-culture practices. This approach will ensure correct
diagnosis and that patients will receive appropriate therapy.
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